GleamWall
中文EN

NUVB Nuvation Bio Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1811063 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY654.2%
TTM net income YoY37.5%
TTM EPS YoY20.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-61.2%
Net margin-67.4%
FCF margin—
EBITDA margin-60.1%

Returns

ROE-49.1%
ROA-19.7%
ROIC (approx.)-30.5%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets70.7%
Debt / equity1.25x
Current ratio7.45x
Interest coverage-5.87x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$62.90M$7.87M
Cost of revenue—$7.08M
Gross profit—$795,000
R&D expense$115.11M$99.12M
SG&A expense$151.56M$69.23M
Operating income-$213.06M-$592.63M
Interest expense$13.68M$341,000
Pretax income-$204.63M-$567.94M
Income tax$0$0
Net income-$204.63M-$567.94M
EBITDA-$211.32M-$591.94M
EPS (basic)-0.60-2.11
EPS (diluted)-0.60-2.11
Weighted avg. shares (diluted)341,541268,772
Balance sheet
Cash & equivalents$164.09M$35.72M
Short-term investments$365.12M$466.97M
Inventory$11.41M$0
Current assets$571.52M$526.25M
PP&E, net$564,000$586,000
Intangibles$11.21M$4.62M
Total assets$594.82M$540.63M
Current liabilities$82.23M$58.24M
Short-term debt$5.72M$6.28M
Long-term debt$47.21M—
Total debt$52.93M—
Total liabilities$289.11M$76.84M
Shareholders' equity$305.72M$463.79M
Net debt-$111.15M—
Shares outstanding346.50M337.84M
Cash flow statement
Operating cash flow-$173.43M-$130.41M
Capital expenditure$8.00M$0
Free cash flow-$181.43M-$130.41M
Investing cash flow$99.52M$122.70M
Financing cash flow$202.53M$331,000
Depreciation & amortization$1.74M$683,000
Stock-based compensation$35.89M$32.27M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.